Results 251 to 260 of about 49,482 (293)

Trafficking first, inflammation next: Epstein-Barr virus B cells seed central nervous system T-cell clusters. [PDF]

Signal Transduct Target Ther
Kim G, Hong JJ.
europepmc   +1 more source

Regulation and Mechanism of Deleted in Breast Cancer‐1 on Dendritic Cell Function in Systemic Lupus Erythematosus

MedComm, Volume 7, Issue 1, January 2026.
LPS‐stimulated DC activation upregulated DBC1. DBC1‐deficient DC ameliorated murine SLE symptoms. DBC1 deficiency suppressed immune responses in DC. DBC1 deficiency lowered STAT5 expression and subsequent phosphorylation. STAT5 overexpression abolished murine SLE remission primed by DBC1 deficiency.
Ze Xiu Xiao, Rongzhen Liang, Yan Liu, Changyuan Huang, Qiannan Fang, Xiaojiang Hu, Julie Wang, Nancy Olsen, Dehua Wu, Song Guo Zheng   +9 more
wiley   +1 more source

T cell engagers: expanding horizons in oncology and beyond. [PDF]

Br J Cancer
Albayrak G, Wan PK, Fisher K, Seymour LW.   +3 more
europepmc   +1 more source

Newly Identified Transcriptomic Biomarkers and Gene Signature of Pathological Complete Response to Induction Chemoimmunotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma

MedComm, Volume 7, Issue 1, January 2026.
Scheme and pathological characteristics of the CheckRad‐CD8 trial cohort used for the transcriptome analyses. (A) Flow diagram depicting the patient cohort and study scheme as the basis for whole transcriptome profiling of samples from locally advanced HNSCC patients treated with induction chemoimmunotherapy (iCIT).
Jian‐Guo Zhou, Markus Eckstein, Haitao Wang, Tianjun Lan, Benjamin Frey, Xin Li, Xiaofan Lu, Gunther Klautke, Thomas Illmer, Maximilian Fleischmann, Simon Laban, Matthias G. Hautmann, Bálint Tamaskovics, Thomas B. Brunner, Arndt Hartmann, Rainer Fietkau, Hu Ma, Antoniu‐Oreste Gostian, Heinrich Iro, Markus Hecht, Udo S. Gaipl   +20 more
wiley   +1 more source

Evaluation of CD3 and CD20 Lymphocytes and Mast Cells in the Microenvironment of Central Giant Cell Granuloma, Peripheral Giant Cell Granuloma, and Giant Cell Tumor of Bone. [PDF]

Diagnostics (Basel)
Fayaq KA, Gharib BT.
europepmc   +1 more source

Beyond PD‐1/PD‐L1: New Immune Checkpoints and Therapeutic Combinations in Cancer Immunotherapy

Medicine Bulletin, Volume 2, Issue 1, Page 61-93, January 2026.
ABSTRACT Recently, immune checkpoint inhibitors (ICIs), particularly PD‐1/PD‐L1 and CTLA‐4 inhibitors, have revolutionized cancer treatment, significantly improving survival rates for various malignancies. However, ICI therapies targeting single checkpoints on T cells still face numerous challenges, such as low response rates and post‐treatment ...
Yangyang Li, Zizhen Kang, Yanyun Du
wiley   +1 more source

Pathology of a Canine Model of Localized Prostate Carcinoma

The Prostate, Volume 86, Issue 1, Page 65-83, January 2026.
ABSTRACT Background Dogs spontaneously develop prostate carcinoma (PC) and share prostate gland anatomy, physiology, and size to men. Over the last 15 years, we have developed and refined a canine model of focal PC to evaluate therapeutic‐diagnostic (theranostic) interventions.
Nathan K. Hoggard, Felipe M. Berg, Marlon R. Szczepaniak, Xinning Wang, Noriko Kantake, Gopalakrishnan Ramamurthy, Li Gong, Eric T. Hostnik, Krishan Kumar, Arijit Ghosh, Dong Luo, Michael V. Knopp, Jill M. Keller, Evan T. Keller, Agata A. Exner, James P. Basilion, Michael F. Tweedle, Thomas J. Rosol   +17 more
wiley   +1 more source

Review: radiotherapy-mediated B cells within the TLS influence the tumor microenvironment. [PDF]

J Immunother Cancer
Yang H, Chen K, Meng Y, Chen Z, Xu Y, Zhou D, Zhou S, Zhang X.   +7 more
europepmc   +1 more source

Pharmacokinetics of Odronextamab, A Bispecific T‐Cell‐Engaging Antibody, in Adult Patients With Relapsed or Refractory B‐Cell Non‐Hodgkin Lymphoma

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 1, January 2026.
ABSTRACT Non‐Hodgkin lymphoma (NHL) is the fifth most common malignancy and accounts for 5% of all cancers in the US, with the largest proportion being B‐cell CD20 positive NHL. Odronextamab is a CD20xCD3 IgG4 bispecific T‐cell‐engaging monoclonal antibody under development for the treatment of relapsed or refractory (R/R) B‐NHL. The objectives of this
Marçal Bravo Padros, Daniela J. Conrado, Kamal Srinivasan, Lutz O. Harnisch, John D. Davis, Min Zhu   +5 more
wiley   +1 more source

CD20+ T Cells in Multiple Sclerosis: From Pathogenesis to Treatment-Induced Depletion. [PDF]

Int J Mol Sci
Mazzeo AC, Calabresi L, Damato V, Spagni G, Massacesi L, Mariottini A.   +5 more
europepmc   +1 more source